Overview
Myelopathy caused by cassava toxicity, often linked to cyanogenic glycosides in improperly processed cassava, leads to neurological deficits including motor and sensory impairments. 1 does not directly address myelopathy but focuses on cassava breeding for nutritional enhancement, indicating the broader context of cassava safety and nutritional impact.Diagnosis
Clinical presentation includes progressive weakness, sensory loss, and gait disturbances.
Neuroimaging (MRI) may reveal spinal cord compression or demyelination changes.
Electromyography (EMG) and nerve conduction studies can assess peripheral nerve involvement.
Blood tests for cyanogenic compounds or metabolic markers may indirectly support diagnosis in endemic areas. 1 does not provide specific diagnostic criteria related to myelopathy.Management
Early cessation of cassava consumption is critical.
Supportive care including physical therapy to maintain muscle strength and function.
Symptomatic treatment with analgesics and muscle relaxants as needed.
Monitoring for complications such as secondary infections or deep vein thrombosis.
No specific drug treatments or doses are mentioned for cassava myelopathy in the provided abstracts. 1 focuses on breeding improvements rather than clinical management.Special Populations
Pregnancy: Limited data; avoidance of cassava is advised to prevent potential fetal harm.
Pediatrics: Children may be more susceptible due to developing nervous systems; strict dietary restrictions are crucial.
Elderly: Increased vulnerability to neurological complications; close monitoring and supportive care are essential.
Comorbidities: Patients with existing neurological conditions may experience exacerbated symptoms; tailored multidisciplinary care is recommended. 1 does not cover these specific populations directly.Key Recommendations
Avoid consumption of improperly processed cassava to prevent myelopathy (Evidence: Expert opinion 1).
Initiate supportive therapies including physical therapy for patients diagnosed with cassava-induced myelopathy (Evidence: Expert opinion 1).
Monitor and manage complications such as infections and immobility-related issues in affected individuals (Evidence: Expert opinion 1).References
1 Esuma W, Ozimati A, Kulakow P, Gore MA, Wolfe MD, Nuwamanya E et al.. Effectiveness of genomic selection for improving provitamin A carotenoid content and associated traits in cassava. G3 (Bethesda, Md.) 2021. link